On 27 November, South African HIV scientists announced a new HIV vaccine trial, HVTN 702, to begin on 30 November. The trial will be conducted on over 5,000 men and women between the ages of 18 and 35 in 15 different locations. Volunteers for the trial will receive either the vaccine or placebo over the course of a year through five periodic injections. Scientists believe, if successful, the trial will be the “final nail in the coffin” for HIV.
[Madison Landry, firstname.lastname@example.org]